Akcea Therapeutics Promotes Kyle Jenne to Chief Commercial Officer
Akcea Therapeutics (NASDAQ: AKCA) has promoted Kyle Jenne to chief commercial officer. Jenne joined Boston-based Akea in 2017 as US commercial head. His appointment comes month after a corporate shakeup that led to the departure of three executives. Akcea is working to commercialize inotersen (Tegsedi), a drug approved by the FDA last year as a treatment for the nerves damage caused by the rare disease hereditary transthyretin amyloidosis.
More from EXOME
Trending on Xconomy
Underwriters and Partners
Xpertise: Watch + Learn
From Our Partners · Special Report
Robert Langer reveals secrets to early-stage biotech success
Advice for funding and future transformational opportunities
Xconomy Insight · Special Report
How to Jump 5 Unforeseen Hurdles to Biotech Success – Startup Sourcebook
Insights, wisdom, and inspiration on what it takes
Xconomy Insight · Webinar
Digital Healthcare Revolution Webinar Series
AI, drug discovery and development, IBM Watson Health, oncology, genomics & more